Patent: RE45822
✉ Email this page to a colleague
Summary for Patent: RE45822
Title: | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
Abstract: | The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent. The adverse-effect agent is covered with a coating that is substantially insoluble in the gastrointestinal tract. In one embodiment, the adverse-effect agent is coated with an outer base-soluble layer and an inner acid-soluble layer. The therapeutic agent can be uncoated or can be coated with a coating having an outer acid-soluble layer and an inner base-soluble layer. The dosage form discourages administration of the therapeutic agent by other than oral administration. |
Inventor(s): | Wright, IV; Curtis (Rockport, MA), Carpanzano; Anthony E. (Sherman, CT) |
Assignee: | Purdue Pharma L.P. (Stamford, CT) |
Application Number: | 13/923,362 |
Patent Claims: | see list of patent claims |
Details for Patent RE45822
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Jubilant Hollisterstier Llc | N/A | positive skin test control-histamine | Injection | 103891 | 03/13/1924 | ⤷ Try a Trial | 2021-08-06 |
Nps Pharmaceuticals, Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | 01/23/2015 | ⤷ Try a Trial | 2021-08-06 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |